Compare Burlington Stores Inc (BURL) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Burlington Stores Inc vs IDEXX Laboratories, Inc. — how do they compare? Burlington Stores Inc trades at $344.28 (market cap $21.04B), while IDEXX Laboratories, Inc. trades at $558 (market cap $42.65B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2× Burlington Stores Inc's market cap, and Burlington Stores Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| BURL | IDXX | |
|---|---|---|
Market Cap | $21.04B | $42.65B |
Sector | Consumer Cyclical | Health |
52-Week High | $347.82 | $766.68 |
52-Week Low | $242.43 | $514.61 |
Enterprise Value | $26.17B | $43.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Burlington Stores (BURL) trades at $327.59, showing minimal daily movement with a slight 0.04% decline. The stock maintains strong bullish technical signals with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. Fundamentally, the company demonstrates robust performance with consistent earnings beats, including Q1 2026 EPS of $2.01 exceeding expectations of $1.80. Revenue growth continues with 2025 reaching $10.63 billion and projected increase to $11.9 billion in 2026.
Outlook remains positive with 94% analyst buy ratings and $364.40 consensus price target representing 11% upside. Key opportunities include margin expansion and store productivity improvements, while risks involve competitive retail pressures and inventory management challenges. The company's strong cash flow generation and debt-to-asset ratio of 19.5% provide financial stability for continued growth initiatives.
IDXX trades at $564.09, up 0.09% with neutral technical signals. The stock shows strong fundamentals with revenue growth to $4.3B in 2025 and consistent earnings beats. Analyst consensus is bullish (59% Buy) with improving cash flow trends. Recent news highlights AI integration in medical devices and upcoming Q2 2026 earnings.
Outlook remains positive driven by innovation and market leadership in pet healthcare. Risks include high valuation multiples and competitive pressures. Institutional sentiment supports growth, but investors should monitor execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Burlington Stores Inc
Burlington is a leading off-price retailer in the US, offering branded apparel, footwear, and home goods at significant discounts. It operates hundreds of stores focused on delivering high-quality products at great value.
Read more on BURL →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
